Does CBG Help Anxiety? New Study Explained

Anxiety disorders are among the most common mental health conditions worldwide. While many people benefit from conventional treatments such as SSRIs, SNRIs, and benzodiazepines, others experience incomplete relief, unwanted side effects, or concerns about dependency. The need for alternative or adjunctive therapies is immediate.

One cannabinoid increasingly entering the spotlight is cannabigerol (CBG). Often referred to as the “mother cannabinoid” because it serves as a precursor to THC and CBD in the cannabis plant, CBG is non-intoxicating and now widely available in oils, capsules, and CBG-dominant flower. Despite its commercial presence, however, it remains largely understudied.

A new research paper¹, “Pharmacokinetic and pharmacodynamic properties of cannabigerol in male mice,” provides important clarity. While early reports and consumer surveys suggest CBG may reduce anxiety, this new research reveals a more nuanced and scientifically intriguing picture.

Does CBG Help Anxiety? Early Evidence

CBG has quietly built a reputation as a calming cannabinoid. In a 2022 online survey, 51.2% of respondents rated CBG-predominant cannabis products as more effective than conventional anxiolytic medications. That is a striking statistic, particularly given how early we are in formal CBG research.

Preclinical work has added to the optimism. The recent paper reviewed studies that previously reported anxiolytic-like effects of CBG at 10 mg/kg in mice and rats. Even more compelling, a placebo-controlled field trial involving 34 human participants found that a single 20 mg oral dose of CBG significantly reduced self-reported anxiety.

These findings fuel consumer demand and position CBG as a promising plant-derived option for those seeking non-intoxicating anxiety support.

However, not all research aligns with that narrative. Other studies have found no significant effect of CBG on anxiety-like behavior. In one rat study using 2.5 mg/kg intraperitoneally, CBG did not alter behavior in the light-dark box test. In a mouse model of post-traumatic stress, CBG at 10 or 30 mg/kg failed to attenuate anxiety-like responses.

Such discrepancies are not unusual in early-stage pharmacology, but they demand explanation.

New Study on CBG Pharmacokinetics Explained

To better understand these inconsistencies, the researchers focused on two key areas: pharmacokinetics (how the drug moves through the body) and pharmacodynamics (how it affects behavior).

Swipe to scroll →

Using a newly developed, highly sensitive LC-MS/MS method, the team quantified CBG and its primary oxidative metabolite, cyclo-CBG, in biological tissues. Male mice were given CBG at 10 mg/kg via intraperitoneal injection, and brain levels were carefully measured.

One of the most important findings was that CBG itself had relatively low brain penetration, with a brain-to-plasma ratio of 0.26. In contrast, cyclo-CBG accumulated in the brain at much higher levels, with a striking brain-to-plasma ratio of 7.1.

This suggests that the metabolite, not just the parent compound, may be crucial in shaping central nervous system effects.

An Unexpected Finding: Anxiogenic at Peak Brain Levels

To align behavioral testing with pharmacokinetics, researchers assessed anxiety-like behavior 30 minutes after CBG administration, the time point corresponding to peak brain CBG levels.

Surprisingly, CBG produced anxiogenic-like effects (increasing anxiety) in the elevated plus maze test. Mice showed reduced open-arm exploration and increased anxiety index scores, behaviors consistent with heightened anxiety rather than reduced anxiety. This finding contrasts with earlier studies that reported anxiolytic-like effects. However, timing appears to be a critical variable.

Previous studies that observed anxiety reduction tested animals approximately 60 minutes after administration, not 30 minutes. It is possible that CBG’s effects shift over time as levels of the parent compound decline and metabolites like cyclo-CBG accumulate.

Dose differences may also contribute. Studies reporting no anxiolytic effect used doses both lower and higher than 10 mg/kg. Cannabinoids frequently demonstrate biphasic effects, where different doses produce opposite outcomes.

How CBG Affects CB1 Receptors (Or Doesn’t)

To determine whether CBG’s anxiogenic-like effect involved CB1 receptors, the primary receptor responsible for THC’s psychoactive effects, researchers administered rimonabant, a CB1 inverse agonist. The anxiety-like response was not reversed by rimonabant. Additionally, CBG only partially mimicked rimonabant’s behavioral profile in the EPM test.

This suggests that CBG’s anxiogenic action at peak brain levels does not depend on CB1 signaling. That is a significant insight, because it indicates CBG operates through mechanisms distinct from THC.

The strong accumulation of cyclo-CBG in brain tissue raises the possibility that this metabolite contributes to the observed behavioral response. However, its direct behavioral effects were not tested in this study, leaving that hypothesis open for future investigation.

Important Limitations

Like all preclinical research, this study has limitations that shape how we interpret its findings.

• All experiments were conducted in adult male mice. We know that sex differences can influence cannabinoid pharmacology, so the results may not generalize to females.
• Behavioral testing occurred at only one dose and one time point. This design provides clarity about peak exposure effects but does not capture how CBG behaves across a range of doses or at later time intervals.
• Only intraperitoneal administration was studied. Human use is typically oral, inhaled, or sublingual, and those routes may produce different pharmacokinetic profiles.
• While CBG and cyclo-CBG were quantified, other metabolites were not measured. Compounds such as 6′,7′-epoxy-CBG could potentially influence behavioral outcomes.

Despite these limitations, the study offers a robust pharmacokinetic framework that strengthens future research.

What This Means for CBG Users

The takeaway is not that CBG “causes anxiety” or that it “doesn’t work.” Rather, the findings emphasize that cannabinoid effects are dynamic, dose-dependent, and time-sensitive. Early human data suggesting reduced self-reported anxiety remain important. But this new research highlights that biological mechanisms may be more complex than previously assumed.

As interest in CBG continues to rise, rigorous pharmacokinetic and pharmacodynamic research will be essential. Understanding how CBG is metabolized, which compounds reach the brain, and how effects shift over time will determine whether it ultimately proves useful as an anxiety therapy.

The Bigger Picture: Expanding Anxiety Treatment Options

The urgency behind this research cannot be overstated. Anxiety disorders can significantly impact a patient’s quality of life. Many individuals continue to seek alternatives because current treatments are not universally effective or tolerable.

Plant-derived cannabinoids like CBG offer intriguing possibilities precisely because they interact with neuromodulatory systems involved in stress and emotional regulation. But moving from consumer enthusiasm to clinical confidence requires careful science.

This study represents an important step forward. It provides validated methods for measuring CBG and cyclo-CBG, clarifies key pharmacokinetic properties, and identifies unexpected anxiogenic-like effects at peak brain exposure.

Rather than dampening interest, these findings sharpen the scientific questions. Does CBG have time-dependent effects? Is cyclo-CBG responsible for central behavioral changes? Could different dosing strategies produce anxiolytic outcomes? And how do these findings translate to humans?

As cannabinoid science matures, studies like this will help ensure that future therapies are built on evidence, not assumption. For those living with anxiety, that commitment to rigorous investigation is ultimately good news.

References:

^{1. Pharmacokinetic and pharmacodynamic properties of cannabigerol in male mice. Tagne, Alex Mabou et al. The Journal of Pharmacology and Experimental Therapeutics, Volume 0, Issue 0, 104308 Pharmacokinetic and pharmacodynamic properties of cannabigerol in male mice – The Journal of Pharmacology and Experimental Therapeutics}